Can antibody prophylaxis allow sparing of other immunosuppressives?

Transplant Proc. 1999 Feb-Mar;31(1-2):1246-8. doi: 10.1016/s0041-1345(98)01982-4.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Cytomegalovirus Infections / epidemiology
  • Daclizumab
  • Drug Administration Schedule
  • Europe
  • Graft Rejection / drug therapy
  • Graft Rejection / pathology
  • Graft Rejection / prevention & control*
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Infusions, Intravenous
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / pathology
  • Muromonab-CD3 / therapeutic use
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Postoperative Complications
  • Steroids / therapeutic use
  • United States

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Steroids
  • Daclizumab
  • Mycophenolic Acid